D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea · Delayed Price · Currency is KRW

87,500

-5,000 (-5.41%)

Jun 30, 2026, 3:30 PM KST

185.25% (1Y)

Market Cap	4.11T +346.6%
Revenue (ttm)	3.01B -71.9%
Net Income	-23.20B
EPS	-774.21
Shares Out	44.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	659,730
Open	91,500
Previous Close	92,500
Day's Range	87,400 - 94,300
52-Week Range	27,825 - 116,600
Beta	1.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 347850

Full Company Profile

Financial Performance

In 2025, D&D Pharmatech's revenue was 4.30 billion, a decrease of -62.42% compared to the previous year's 11.44 billion. Losses were -23.55 billion, -17.71% less than in 2024.

Financial Statements